Health Care • Biotechnology: Pharmaceutical Preparations
$25.70 ▼ -1.10
(-4.10%)
MKT CAP: $2.93B • VOL: 2.35M
52W L $12 52W H $28
NRIX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-11-30 | FY 2024
FILED 2024-11-30 | FY 2023
FILED 2023-11-30 |
|---|---|---|---|
| Revenue (Total Sales) | $84.0M | $54.5M | $77.0M |
| YoY Revenue Growth % | +54.0% | -29.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$285.7M | -$213.0M | -$155.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$264.5M | -$193.6M | -$143.9M |
| EBITDA (Normalized) | -$274.5M | -$205.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$249.5M | -$172.6M | -$81.4M |
| Capital Expenditures (CapEx) | $14.0M | $9.3M | — |
| Free Cash Flow (FCF) | -$263.5M | -$181.9M | -$81.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -40.4% | — |
| Cash & Short-Term Equivalents | $247.0M | $110.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $538.7M | $527.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NRIX.